-transparent.png){kind=logo}
Dichloromethylene diphosphonate (Cl2MDP), a powerful inhibitor of bone resorption, was given (daily dose: 500 mg i.v. for 2 months and then 1600 mg p.o.) to five patients with Paget's disease after 8 months treatment with 50-100 MRC u/day of human calcitonin (CT). During treatment with CT plasma alkaline phosphatase (ALP) and urinary hydroxyproline (HOP) levels fell to about 60% of pretreatment values within the first 2 months in all the patients. Cl2MDP therapy resulted in a further drop of urinary HOP to 20% of baseline values, while serum ALP rose impressively during the first 2 weeks of therapy and then slowly fell to 25% of baseline values. We conclude that Cl2MDP can induce a further biochemical response after the so-called plateau phenomenon to CT and that it may represent the therapy of choice for severe Paget's disease.
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
January 1980,
Advances in experimental medicine and biology,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
October 1980,
Arthritis and rheumatism,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
February 1985,
Tumori,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
April 1982,
La Nouvelle presse medicale,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
May 1984,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
January 1983,
Metabolic bone disease & related research,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
March 1976,
Lancet (London, England),
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
January 1984,
Metabolic bone disease & related research,
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
September 1979,
Lancet (London, England),
S Adami, and
G Guarrera, and
G Salvagno, and
G Spiazzi, and
G Marini, and
S Rosini, and
V Lo Cascio
April 1976,
Lancet (London, England),
